{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:16:48Z","timestamp":1790482608136,"version":"4.1.0"},"reference-count":6,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal transplant recipients (<jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>) who are seropositive for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> (R+) are considered to be at intermediate risk for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease. Current guidelines recommend high\u2010dose valganciclovir (<jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content>) prophylaxis because of limited data on the efficacy of low\u2010dose <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content>. We describe our experience with using low\u2010dose <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> in R+ <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>. We retrospectively reviewed a cohort of 316 R+ <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content> at our institution between 2002 and 2006. The primary endpoint was <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease at 1 year post transplant. The incidence of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease at 12 months after transplantation was only 3% (6\/221) in the D+R+ and 4% (4\/95) in the D\u2212R+ <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>. Low\u2010dose <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> was effective at preventing <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease in intermediate\u2010risk (R+) <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/tid.12780","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T06:08:52Z","timestamp":1506060532000},"source":"Crossref","is-referenced-by-count":10,"title":["Low\u2010dose valganciclovir prophylaxis for cytomegalovirus in intermediate\u2010risk (R+) renal transplant recipients: Single\u2010center experience"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-9173","authenticated-orcid":false,"given":"Salman","family":"Khan","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Fischman","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Huprikar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12006"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31828ee12e"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12609"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12349"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.05.004"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:08:39Z","timestamp":1696043319000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,3]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/tid.12780"],"URL":"https:\/\/doi.org\/10.1111\/tid.12780","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,3]]},"article-number":"e12780"}}